These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Author: Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.
    Journal: Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926.
    Abstract:
    BACKGROUND & OBJECTIVE: The molecular predictor for cisplatin sensitivity in advanced non-small cell lung cancer (NSCLC) is still an open question at present. The purpose of this study was to evaluate the relationship of the cisplatin sensitivity/prognosis with the expression of excision repair cross complement-1 (ERCC-1), metallothionein (MT), and p53 in the paraffin-embedded tissue of advanced non-small cell lung cancer (NSCLC). METHODS: From January 1994 to December 2001, 51 pathologically confirmed advanced NSCLC patients were included. All patients received cisplatin contained regimen chemotherapy (Gemzar + DDP or NVB + DDP) as the first line treatment. At the same time, the tumor samples were collected and the expression of ERCC-1, MT, and p53 in the tumor samples were examined by immunohistochemical method. The response rates and survival data were analyzed according to the over-expression or not of these three parameters (negative group/over-expression group). The response rates were compared by Chi(2) test. Kaplan-Meier method and Cox proportional hazards model were used for survival analysis. RESULTS: In these 51 patients, the expression rates of ERCC-1, MT, and p53 were 42.8%, 57.5%, and 37.8%, respectively. The response rates in negative group/over-expression group of ERCC-1, MT, and p53 were 33.3%/16.7%, 35.3%/27.3%, and 21.4%/35.3%, respectively (1.99, 1.29, and 0.61 times, respectively, P >0.05). The response rate in both ERCC-1 and MT negative group was 37.5%. In both ERCC-1 and MT over-expression (co-expression) group, the response rate was 14.3%. The former was 2.6 times of the latter (P >0.05). The average survival time in negative group/over-expression groups were 621/523 days (for ERCC-1), 556/479 days (for MT), 599/416 days (for p53), respectively. ERCC-1, MT, or p53 over-expression group showed poorer prognosis than those of negative group by Kaplan-Meier analysis. But in multivariate analysis, only p53 over-expression was an independent poor prognostic factor of survival time (Cox regression, P=0.009). CONCLUSION: Whether over-expression of ERCC-1 and MT can be used as a molecular marker of cisplatin resistance in advanced NSCLC patients need further study. Over-expression of p53 predicates poor prognosis for patients with advanced NSCLC.
    [Abstract] [Full Text] [Related] [New Search]